ストックスクリーナーアプリを入手
13.26
1.69%
0.2284
前日終値:
$13.03
開ける：
$13.11
24時間の取引高:
175.81K
Relative Volume:
0.45
時価総額：
$188.36M
収益：
$13.11M
当期純損益:
$-124.02M
株価収益率:
-0.9297
EPS:
-14.261
ネットキャッシュフロー:
$-107.25M
1週間 パフォーマンス:
+4.25%
1か月 パフォーマンス:
-4.68%
6か月 パフォーマンス:
-26.88%
1年 パフォーマンス:
-32.33%
1日の値動き範囲:
$12.72
$13.49
1週間の範囲:
$12.00
$14.09
52週間の値動き範囲:
$11.60
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
名前
Tonix Pharmaceuticals Holding Corp
セクター
電話
212-980-9155
住所
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
13.26 | 185.10M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
424.80 | 109.34B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
702.13 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
797.33 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.67 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
295.67 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-04-18 | 開始されました | Noble Capital Markets | Outperform |
| 2019-04-18 | アップグレード | ROTH Capital | Neutral → Buy |
| 2017-08-18 | アップグレード | ROTH Capital | Neutral → Buy |
| 2016-09-07 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2016-02-17 | 繰り返されました | Oppenheimer | Outperform |
| 2015-11-04 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-06-12 | 開始されました | Oppenheimer | Outperform |
| 2015-02-17 | 繰り返されました | ROTH Capital | Buy |
| 2014-09-29 | 繰り返されました | ROTH Capital | Buy |
すべてを表示
Tonix Pharmaceuticals Holding Corp (TNXP) 最新ニュース
symbol__ Stock Quote Price and Forecast - CNN
Cash per share of Tonix Pharmaceuticals Holding Corp. – DUS:TPM0 - TradingView
Tonix Pharmaceuticals (TNXP) to Release Quarterly Earnings on Monday - MarketBeat
TD Cowen initiated coverage on Tonix Pharma with a new price target - Quantisnow
TD Cowen initiates Tonix Pharma stock with buy rating, $22 target - Investing.com India
Tonix Pharmaceuticals Holding (TNXP) price target decreased by 15.76% to 55.42 - MSN
Tonix Pharmaceuticals Holding Corp. Files Form 8-K Current Report with NASDAQ Listing Details (May 1, 2026) - Minichart
Tonix Pharmaceuticals (NASDAQ: TNXP) gives early look at Q1 2026 sales - Stock Titan
TNXP Stock Price, Quote & Chart | TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) - ChartMill
Tonix Pharmaceuticals (TNXP) Proxy filing Summary - Quartr
Tonix Pharmaceuticals (TNXP) Announces Phase 2 Study Plans for L - GuruFocus
Tonix plans Phase 2 Lyme disease prevention study in 2027 - Investing.com UK
Tonix plans Phase 2 Lyme disease prevention study in 2027 By Investing.com - Investing.com Australia
Tonix Pharma Advances TNX-4800 Lyme Disease Prevention Program - TipRanks
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symp - The Manila Times
Tonix (NASDAQ: TNXP) plans Phase 2 Lyme antibody study for 2027 - Stock Titan
A two-dose Lyme prevention antibody is planned for a U.S. field study - Stock Titan
Tonix Pharmaceuticals stock hits new 52-week low: What's driving the action? - MSN
Tonix Pharmaceuticals Stock Jumps Into Retail Spotlight After $25M Buyback Boost — Traders See ‘Blueprint For Rerating’ - MSN
(TNXP) Risk Channels and Responsive Allocation - Stock Traders Daily
Tonix Pharmaceuticals Holding Corp (STU:TPM0) Stock Price & 30 Year Financial Data - GuruFocus
Wall Street Zen Downgrades Tonix Pharmaceuticals (NASDAQ:TNXP) to Sell - MarketBeat
Tonix Pharmaceuticals Showcases Promising Preclinical Immuno-Oncology Advances with TNX-1700 and TNX-4700 at AACR 2026 1 - Minichart
Tonix Pharma Highlights Preclinical Progress in Oncology Pipeline - TipRanks
Preclinical cancer data for Tonix (NASDAQ: TNXP) TNX-1700 and TNX-4700 - Stock Titan
Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026 - Yahoo Finance
Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
(TNXP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development - Sahm
Tonix publishes pharmacokinetic study on fibromyalgia drug By Investing.com - Investing.com Australia
Tonix Pharmaceuticals (TNXP) Reports Positive Findings on TNX-10 - GuruFocus
Tonix publishes pharmacokinetic study on fibromyalgia drug - Investing.com
Tonix Pharmaceuticals Announces Publication of Steady-State - GlobeNewswire
Analyst Upgrade: Can Tonix Pharmaceuticals Holding Corp stock outperform in a bear marketWeekly Earnings Recap & Reliable Price Breakout Alerts - baoquankhu1.vn
TNXP Options Volatility — NASDAQ:TNXP - TradingView — Track All Markets
TNXP Options Chain — NASDAQ:TNXP - TradingView
Profit Recap: Will Tonix Pharmaceuticals Holding Corp announce a stock split2026 Analyst Calls & Daily Chart Pattern Signals - baoquankhu1.vn
Will Tonix Pharmaceuticals Holding Corp stock benefit from M AInflation Watch & Daily Stock Trend Watchlist - baoquankhu1.vn
Why Tonix's External Atty Saw GC Role As A 'Natural Choice' - Law360
Liquidity Mapping Around (TNXP) Price Events - Stock Traders Daily
Tonix Pharmaceuticals Holding Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Tonix Pharmaceuticals Holding Corp (TNXP) 財務データ
収益
当期純利益
現金流量
EPS
Tonix Pharmaceuticals Holding Corp (TNXP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| LEDERMAN SETH | Chief Executive Officer |
Mar 18 '26 |
Buy |
14.89 |
15,000 |
223,350 |
15,001 |
| Taylor Carolyn E. | Director |
Aug 21 '25 |
Buy |
36.03 |
418 |
15,061 |
418 |
| Treco James | Director |
Aug 20 '25 |
Buy |
36.00 |
250 |
9,000 |
250 |
| LEDERMAN SETH | Chief Executive Officer |
May 15 '25 |
Buy |
21.55 |
4,000 |
86,200 |
4,005 |
1.94%
1.54%
大文字化:
|
ボリューム (24 時間):